The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 02 May 2017 it purchased 1,329 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a price of 4.9p per Ordinary Share (the “First Purchase”). The Company has also received notification that on 03 May 2017 Vulpes purchased a further 240 Ordinary Shares at a price of 4.85p per Ordinary Share (the “Second Purchase”) (together with the First Purchase, “the Purchases”). Following the Purchases Vulpes has a total direct and indirect interest in 54,145,284 equivalent to 18.38% of Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 54,145,284 Ordinary Shares of the Company representing 18.38% of the issued share capital of the Company.